CoChat

Characterization of on-target adverse events caused by TRK inhibitor therapy

Open access
Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C.J., Murciano-Goroff, Y.R., Rosen, E., Guo, R., Basu, E., Li, B.T., Harding, J.J., Iyer, G., Jhaveri, K., Gounder, M.M., Shukla, N.N., Roberts, S.S., Glade-Bender, J., Kaplanis, L., Schram, A., Hyman, D.M., Drilon, A. · 2020 · Annals of Oncology
Cited by 95

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose. The TRK pathway controls appetite, balance, and pain sensitivity. While these functions are reflected in the on-target adverse effects (AEs) observed with TRK inhibition, these AEs remain under-recognized, and pain upon drug withdrawal has not previously been reported. As TRK inhibitors are approved by multiple regulatory agencies for TRK or ROS1 fusion-positive cancers, characterizing these AEs and corresponding management strategies is crucial. Methods. Patients with advanced or unresectable solid tumors treated with a TRK inhibitor were retrospectively identified in a search of clinical databases. Among these patients, the frequency, severity, duration, and management outcomes of AEs including weight gain, dizziness or ataxia, and withdrawal pain were characterized. Results. Ninety-six patients with 15 unique cancer histologies treated with a TRK inhibitor were identified. Weight gain was observed in 53% (95% CI, 43%-62%) of patients and increased with time on TRK inhibition. Pharmacologic intervention, most commonly with GLP-1 analogs or metformin, appeared to result in stabilization or loss of weight. Dizziness, with or without ataxia, was observed in 41% (95% CI, 31%-51%) of patients with a median time to onset of 2 weeks (range, 3 days to 16 months). TRK inhibitor dose reduction was the most effective intervention for dizziness. Pain upon temporary or permanent TRK inhibitor discontinuation was observed in 35% (95% CI, 24%-46%) of patients; this was more common with longer TRK inhibitor use. TRK inhibitor re-initiation was the most effective intervention for withdrawal pain. Conclusions. TRK inhibition-related AEs including weight gain, dizziness, and withdrawal pain occur in a substantial proportion of patients receiving TRK inhibitors. This safety profile is unique relative to other anticancer therapies and warrants careful monitoring. These on-target toxicities are manageable with pharmacologic intervention and dose modification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.05.006

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 95

Metadata

Authors
Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C. J., Murciano-Goroff, Y. R., Rosen, E., Guo, R., Basu, E., Li, B. T., Harding, J. J., Iyer, G., Jhaveri, K., Gounder, M. M., Shukla, N. N., Roberts, S. S., Glade-Bender, J., Kaplanis, L., Schram, A., Hyman, D. M., & Drilon, A.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2020-09
Volume
31
Issue
9
Pages
1207-1215
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3024986856
Cited by
95
References
4
FWCI
4.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of on-target adverse events caused by TRK inhibitor therapy. https://app.cochat.ai/papers/10.1016/j.annonc.2020.05.006
The paper
Liu, D., Flory, J., Lin, A., Offin, M., Falcon, C. J., Murciano-Goroff, Y. R., Rosen, E., Guo, R., Basu, E., Li, B. T., Harding, J. J., Iyer, G., Jhaveri, K., Gounder, M. M., Shukla, N. N., Roberts, S. S., Glade-Bender, J., Kaplanis, L., Schram, A., . . . Drilon, A. (2020). Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.05.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.